Search for: "DOW PHARMACEUTICAL SCIENCES, INC."
Results 21 - 40
of 130
Sorted by Relevance
|
Sort by Date
14 Aug 2011, 9:11 am
Merrell Dow Pharms., Inc., 509 U.S. 579 (1993). [read post]
27 Mar 2009, 7:00 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993)). [read post]
18 Mar 2011, 1:28 pm
Merrell Dow Pharmaceuticals, Inc. laid down the standard for admissibility of expert testimony. [read post]
22 Jul 2008, 10:42 am
Merrell Dow Pharms. [read post]
15 May 2014, 9:36 am
Novartis Pharmaceuticals Corp., --- F.3d ---, 2014 WL 1328182 (9th Cir. [read post]
18 Sep 2019, 10:02 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S. [read post]
20 Mar 2012, 8:54 am
Merrill Dow Pharmaceuticals, Inc., in which federal judges were directed to serve as “gatekeepers,” the Federal Judicial Center published the First Edition of the Reference Manual on Scientific Evidence, which became the leading reference source for federal judges seeking an understanding of difficult issues involving scientific testimony. [read post]
28 Apr 2008, 6:06 am
Merrell Dow Pharmaceuticals, Inc. [read post]
30 Oct 2013, 10:57 am
Myriad Genetics, Inc., 133 S. [read post]
11 Mar 2011, 2:03 pm
Merrell Dow Pharmaceuticals, Inc., the United States Supreme Court ruled that federal judges may no longer use the proxy of general acceptance by specialists as the test for determining the admissibility of scientific testimony. [read post]
20 Aug 2012, 11:04 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993)? [read post]
20 Aug 2012, 11:04 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993)? [read post]
18 Sep 2019, 10:02 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S. [read post]
19 Nov 2023, 2:31 pm
Merrell Dow Pharmaceuticals, Inc.,[2] The Supreme Court suggested that peer review of studies relied upon by a challenged expert witness should be a factor in determining the admissibility of that expert witness’s opinion. [read post]
21 Oct 2018, 10:29 am
Merrell Dow Pharmaceuticals, Inc., U.S. [read post]
18 Apr 2016, 9:58 am
Lexmark International, Inc., No. 15-1189 (unreasonable restraints on downstream uses) Obviousness: Cubist Pharmaceuticals, Inc. v. [read post]
6 Jun 2013, 12:15 am
The doctrine of inherent anticipation (particularly after Schering Co. v Geneva Pharmaceuticals Inc. et Al., commented here - see also, in the UK, Merrell Dow v H N Norton & Co), may lead to similar distortions. [read post]
8 Apr 2010, 9:27 am
Patrick Gruber, CEO, Gevo, Inc., recognizing his accomplishments in creating and commercializing a new plastic made from annually renewable resources. [read post]
19 Sep 2011, 6:20 am
Merrell Dow Pharmaceuticals are meant to prevent theories based on shaky science from cluttering up court proceedings and confusing juries. [read post]
12 Jun 2023, 1:09 pm
In Matrixx Initiatives, Inc. v. [read post]